ChemoCentryx: Q2 Earnings Insights

05:36pm, Monday, 09'th Aug 2021
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56), which missed the e
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market clos
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.

ChemoCentryx: CRL Less Likely

11:04am, Sunday, 25'th Jul 2021
In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date.

Is Now the Time to Buy ChemoCentryx Stock?

06:44am, Saturday, 10'th Jul 2021
Analysts following this risky biotech stock have changed their tune.
ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7.
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) against certain of its c

Why This ChemoCentryx Analyst Is Bullish

03:20pm, Tuesday, 06'th Jul 2021
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ:CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a  Buy rating on

ChemoCentryx Stock Is Approaching A Key Level

01:55pm, Tuesday, 06'th Jul 2021
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmi
New York, New York--(Newsfile Corp. - July 6, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of ChemoCentryx, Inc.Shareholders w
New York, New York--(Newsfile Corp. - July 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibod
Los Angeles, California--(Newsfile Corp. - July 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ChemoCentryx, Inc. ("
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE